SCWorx Announces Resumption of Nasdaq Trading and Highlights Improved Operating Performance and Growth Strategy

SCWorx slashes losses, boosts gross profit, and regains Nasdaq compliance after capital raise.

What the company is saying

SCWorx Corp. is emphasizing a turnaround narrative, highlighting the resumption of Nasdaq trading following a Hearings Panel decision that found the company back in compliance, albeit with a one-year Panel Monitor. President and CEO Tim Hannibal frames the update as proof of improved company economics, citing investments in technology, healthcare data assets, and customer relationships. The company stresses sharp improvements in gross profit and cash utilization, attributing the reduced net loss to both operational gains and the elimination of $1.7 million in interest expense and debt discount from now-redeemed convertible notes. SCWorx points to new customer agreements in 2026, including a not-for-profit teaching hospital and a two-year deal with a major Massachusetts integrated delivery network, as evidence of commercial traction. The release underscores ongoing investment in AI-enabled data management and positions recurring and multi-year revenue as central to future strategy. The tone is confident, with management asserting that recent operational improvements create a stronger foundation for scalable growth.

What the data suggests

The disclosed numbers show modest revenue growth but dramatic improvement in profitability and cash flow. Second quarter 2026 revenue was $706,000, up from $683,000 a year earlier, while gross profit jumped 83% to $330,000 from $180,000. For the first half of 2026, gross profit rose 122% to $705,000 on revenue of $1.45 million, versus $317,000 and $1.40 million in the prior-year period. Net loss for Q2 narrowed to $121,000 from $1.9 million, and for the first six months to $295,000 from $2.4 million. The company attributes this to higher gross profit and the removal of $1.7 million in interest expense and debt discount, with operating expenses flat. Cash used in operations dropped to $258,000 from $1.1 million, and cash on hand at June 30, 2026 was $1.3 million. A $938,000 capital raise in September 2026 further bolstered liquidity. While the company reports new customer wins and expanded AI capabilities, it does not quantify the impact of these on recurring revenue or future growth, leaving the scale of strategic progress unmeasured.

Analysis

The announcement presents a positive tone, highlighting SCWorx's resumption of Nasdaq trading, improved financials, and strategic progress. The measurable evidence is strong for operational improvement: revenue, gross profit, net loss, and cash flow all show clear year-over-year gains, and the company provides specific figures for each. However, the narrative is somewhat inflated by forward-looking statements about AI-enabled scalability, recurring revenue, and strategic value, which are not yet supported by quantified results or detailed customer metrics. The company references new agreements and customer wins, but does not disclose their financial impact or recurring revenue contribution. While the operational improvements are real and immediate, the broader claims about future scalability and value creation are aspirational. There is no indication of a large capital outlay with deferred returns, and the financial improvements are already being realized.

Risk flags

• ●SCWorx remains under a one-year Nasdaq Panel Monitor, meaning any compliance breach will trigger an immediate delisting determination without a cure period. This creates heightened regulatory risk and requires flawless execution on compliance.
• ●Despite improved profitability, the company is still operating at a net loss and relies on external capital, as evidenced by the $938,000 private placement in September 2026. Sustained losses or inability to further raise capital could pressure liquidity.
• ●The announcement references new customer agreements and AI-enabled capabilities but does not disclose their financial impact or recurring revenue contribution. This lack of detail on the scale and stickiness of new business leaves future revenue visibility uncertain.
• ●SCWorx operates in a highly competitive healthcare technology market, and its ability to convert operational improvements into durable revenue growth and positive cash flow is unproven. Execution risk remains high given the company's small scale and ongoing transformation.
• ●The company's improved net loss is partly due to the elimination of $1.7 million in interest expense and debt discount from convertible notes that are no longer outstanding. This one-time benefit will not recur, so future profitability depends on continued operational gains.

Bottom line

SCWorx has delivered a clear operational turnaround, with sharply reduced net losses, higher gross profit, and lower cash burn, all supported by specific year-over-year figures. The company has regained Nasdaq compliance and raised new capital, strengthening its balance sheet. However, it is still loss-making and must maintain strict compliance during the one-year Panel Monitor period, with no margin for error. While management highlights new customer wins and AI-driven efficiencies, the absence of quantified recurring revenue or customer retention metrics means the scale of future growth is unproven. Investors should focus on whether SCWorx can translate operational improvements into sustained revenue growth and positive cash flow. The most important takeaway is that the company has bought itself time and credibility, but must now deliver measurable, recurring growth to justify its turnaround story.

Announcement summary

(NASDAQ:WORX) SCWorx Corp. announced the resumption of trading of its common stock on The Nasdaq Capital Market following the Nasdaq Hearings Panel's October 2, 2026 decision granting the company's request for reconsideration of its September 17, 2026 delisting decision. The Panel determined that SCWorx had regained compliance with Nasdaq's continued listing requirements and approved continued listing, subject to a one-year Panel Monitor. Tim Hannibal, President and Chief Executive Officer of SCWorx, stated that the company has significantly improved its economics over the past year while continuing to invest in technology, healthcare data assets, and customer relationships. For the second quarter of 2026, SCWorx generated revenue of approximately $706,000, compared with approximately $683,000 in the second quarter of 2025. Gross profit increased approximately 83% to $330,000, compared with $180,000 in the prior-year period. For the first six months of 2026, gross profit increased approximately 122% to $705,000, compared with $317,000 in the prior-year period, with revenue of approximately $1.45 million compared to $1.40 million. The company's net loss for the second quarter declined to $121,000, compared with a net loss of $1.9 million in the second quarter of 2025. For the first six months of 2026, net loss was $295,000, compared with $2.4 million during the comparable period in 2025. The decrease in net loss was attributed to increased gross profit and the absence in 2026 of $1.7 million of interest expense and amortization of debt discount recorded in the first six months of 2025 related to convertible notes that are no longer outstanding; operating expenses were essentially unchanged. Cash used in operating activities declined to $258,000 during the first six months of 2026, compared with $1.1 million during the comparable period in 2025. SCWorx had cash of $1.3 million at June 30, 2026 and, in September 2026, raised gross proceeds of $938,000 in a private placement of common stock and warrants. The company has continued to expand its AI-enabled Data Management Model, combining large language models with its healthcare data assets, attribute catalog, classification methodologies, and human quality assurance. In 2026, SCWorx announced new agreements and customer wins, including a new not-for-profit teaching hospital utilizing SCWorx data-management capabilities in support of a Workday implementation and a new two-year agreement with one of Massachusetts' largest integrated delivery networks. SCWorx is focused on expanding its healthcare customer base, increasing recurring and multi-year revenue, improving gross margins and operating leverage through automation and AI-enabled workflows, and expanding the strategic value and application of its healthcare data and technology. The company believes its Nasdaq listing provides a platform to increase visibility among investors, healthcare customers, strategic partners, and potential sources of capital. SCWorx must maintain compliance with Nasdaq's continued listing requirements during the one-year Panel Monitor period, during which any deficiency would result in a Staff Delisting Determination without the benefit of a compliance plan or cure period. Management believes the company is operating from a significantly stronger foundation than a year ago, with improved gross profitability, reduced net loss, reduced operating cash utilization, continued customer wins, and investments in technology and AI-enabled capabilities.

Disagree with this article?